07.20.16
John Demaree has been promoted to vice president, Oncology Marketing, Astellas Americas. Mr. Demaree will lead the oncology marketing team for in-market products, preparation for new oncology product launches and strategic planning and collaboration with the company's partner organizations in the Americas. He reports to Mark Reisenauer, senior vice president, Oncology Business Unit, Astellas Americas.
Mr. Demaree has more than 25 years of experience working in the pharmaceutical industry, with 20 years in oncology. Mr. Demaree previously served as executive director, Oncology Marketing, where he helped execute the launch of XTANDI and promotion of Tarceva. He also worked at Abbott as the general manager for oncology business development and alliance management and held roles of increasing responsibility at Novartis and Eli Lilly and Co.
"Astellas is committed to making a difference in the lives of cancer patients through an emphasis on innovation and R&D," said Mr. Reisenauer. "We are confident that John's commercial experience in oncology will help us make strides in improving care for the patients we serve."
Mr. Demaree has more than 25 years of experience working in the pharmaceutical industry, with 20 years in oncology. Mr. Demaree previously served as executive director, Oncology Marketing, where he helped execute the launch of XTANDI and promotion of Tarceva. He also worked at Abbott as the general manager for oncology business development and alliance management and held roles of increasing responsibility at Novartis and Eli Lilly and Co.
"Astellas is committed to making a difference in the lives of cancer patients through an emphasis on innovation and R&D," said Mr. Reisenauer. "We are confident that John's commercial experience in oncology will help us make strides in improving care for the patients we serve."